close
About Ubix
Ubix Therapeutics develops novel anti-cancer drugs based on Degraducer® platform technology.
Degraducer® is a powerful, next-generation inhibitor technology that enables targeting of disease-related targets that were previously undruggable.
We are developing novel anti-cancer therapies based on conscientious research and understanding of the human immune system and target proteins. Our goal is to increase life span and improve quality of life for affected patients.
Prof. Sang-Ki Rhee
Chair Professor of Soonchunhyang University
CEO, Bioholdings
(Previous) President, Korea Research Institute of Bioscience and Biotechnology
B.A. in microbiology, Seoul National University
Prof. Dong-Yun Shin
College of Pharmacy at Gachon University
Research field: medicinal chemistry, small molecule drug development
Ph.D., School of Pharmacy at Seoul National University
Prof. Sung-Jean Park
College of Pharmacy at Gachon University
Research field: protein structure analysis, efficacy evaluation based on protein
Ph.D., School of Pharmacy at Seoul National University
Prof. Jun-Goo Jee
College of Pharmacy at Kyungpook National University
Research field: CADD based on protein structure, algorithm developments
Ph.D., School of Pharmacy at Seoul National University
Prof. Byung-Hoon Lee
Department of New Biology at DGIST
Research field: Ubiquitin, proteasome-related pathway, drug assay
Ph.D., in microbiology, Seoul National University